Claims for Patent: 10,106,579

Summary for Patent: 10,106,579

Title:	Modulation of complement activity
Abstract:	The present invention provides modulators of complement activity. Also provided are methods of utilizing such modulators as therapeutics.
Inventor(s):	Hoarty Michelle Denise, Dhamnaskar Ketki Ashok, Elbaum Daniel, Josephson Kristopher, Larson Kelley Cronin, Ma Zhong, Nims Nathan Ezekiel, Ricardo Alonso, Seyb Kathleen, Tang Guo-Qing, Treco Douglas A., Wang Zhaolin, Ye Ping, Zheng Hong, Perlmutter Sarah Jacqueline, Hammer Robert Paul
Assignee:	Ra Pharmaceuticals, Inc.
Application Number:	US15318063
Patent Claims:	2. The polypeptide of claim 1 , further comprising a bridging moiety between two amino acids.4. The polypeptide of claim 2 , wherein the bridging moiety comprises a feature selected from the group consisting of a disulfide bond claim 2 , an amide bond (lactam) claim 2 , a thioether bond claim 2 , an aromatic ring claim 2 , an unsaturated aliphatic hydrocarbon chain claim 2 , a saturated aliphatic hydrocarbon chain and a triazole ring.5. The polypeptide of claim 1 , wherein the polypeptide comprises a cyclic loop claim 1 , wherein the cyclic loop is of a length selected from the group consisting of 1 amino acid claim 1 , 2 amino acids claim 1 , 3 amino acids claim 1 , 4 amino acids claim 1 , 5 amino acids claim 1 , 6 amino acids claim 1 , 7 amino acids claim 1 , 8 amino acids claim 1 , 9 claim 1 , amino acids claim 1 , 10 amino acids claim 1 , 11 amino acids claim 1 , 12 amino acids claim 1 , 13 amino acids claim 1 , 14 amino acids claim 1 , 15 amino acids and 16 amino acids.6. The polypeptide of claim 4 , wherein said feature comprises an aromatic ring and wherein said bridging moiety is formed by reaction with a poly(bromomethyl)benzene.7. The polypeptide of claim 6 , wherein the poly(bromomethyl)benzene is selected from the group consisting of 1 claim 6 ,2-bis(bromomethyl)benzene claim 6 , 1 claim 6 ,3-bis(bromomethyl)benzene and 1 claim 6 ,4-bis(bromomethyl)benzene.8. The polypeptide of wherein the reagent is 1 claim 7 ,3-bis(bromomethyl)benzene.9. The polypeptide of claim 4 , wherein said feature comprises an aromatic ring and wherein said bridging moiety is produced by reaction with a compound selected from the group consisting of 2 claim 4 ,6-bis(bromomethyl)pyridine claim 4 , (E)-1 claim 4 ,4-dibromobut-2-ene and 1 claim 4 ,2-bis(bromomethyl)-4-alkylbenzene.10. The polypeptide of claim 1 , wherein said polypeptide is selected from the group consisting of SEQ ID NOs 177 claim 1 , 184 claim 1 , and 194.11. The polypeptide of claim 10 , wherein said polypeptide comprises SEQ ID NO: 177.12. The polypeptide of claim 10 , wherein said polypeptide comprises SEQ ID NO: 184.13. The polypeptide of claim 10 , wherein said polypeptide comprises SEQ ID NO: 194.14. A composition comprising the polypeptide of any of claim 10 , claim 10 , and - and an acceptable carrier or excipient.15. The composition of comprising an excipient claim 14 , wherein said excipient comprises a pharmaceutically acceptable excipient.16. A method of inhibiting C5 cleavage in a cellular system claim 15 , said method comprising contacting said cellular system with the composition of .17. The method of claim 16 , wherein said polypeptide inhibits the cleavage of C5 with an ICof less than 50 nM.18. The method of claim 16 , wherein said cellular system is a human subject.19. The method of claim 18 , wherein said human subject comprises a complement-related disease claim 18 , disorder and/or condition.20. The method of claim 19 , wherein said complement-related disease claim 19 , disorder and/or condition is selected from the group consisting of an inflammatory indication claim 19 , a wound claim 19 , an injury claim 19 , an autoimmune disease claim 19 , a vascular indication claim 19 , a neurological indication claim 19 , a kidney-related indication claim 19 , an ocular disease claim 19 , paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.